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ABSTRACT 
Antimicrobial resistance is becoming a global health concern; as such, the need for new 
effective treatments and preventive measures is increasing. Poly(para-phenylene ethynylene) 
(PPE)- and poly(para-phenylene vinylene) (PPV)-poly[(2-(methacryloyloxy)ethyl) 
trimethylammonium chloride] (PMETAC) graft copolymers were tested against a range of 
clinically and industrially relevant bacteria and results showed many of these conjugated 
polyelectrolytes (CPE’s) to be active. Of all of the compounds tested, PPE-g-PMETAC (low 
molecular weight, LMW) had greatest antimicrobial activity, especially against Enterococcus 
faecium, Methicillin resistant Staphylococcus aureus (MRSA), Escherichia coli and 
Acinetobacter baumannii. 
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INTRODUCTION 
Antimicrobial resistance is a global health concern; as such, the need for new effective 
treatments and preventative measures is increasing. In Europe in 2007, 400,000 infections 
caused by multidrug-resistant (MDR) bacteria resulted in 25,000 attributable deaths and more 
than 1.5 billion dollars in annual spend to cover the extra hospital costs and productivity losses.1 
Both Gram negative and Gram positive bacteria are common causes of hospital acquired 
infections. In the clinical setting, there are a number of bacteria capable of 'escaping' the 
biocidal action of antibiotics. These bacteria include Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter spp., acronymically dubbed 'the ESKAPE pathogens'.1 The normal flora of the 
skin is an important source of serious post operational infections with the involvement of skin 
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organisms such as Staphylococcus epidermidis being widely acknowledged.2  Furthermore, 
modern food production facilitates the emergence and spread of resistance through the 
intensive use of antimicrobial agents and international trade of both animal and food products.3 
In order to control the spread of MDR bacteria, a strategy to reduce the use of antibiotics and 
prevent bacterial transmission between patients carriers is needed.4 A number of bacteria are 
now also demonstrating an alarming increase in their reduced susceptibility to commonly used 
biocides e.g. chlorhexidine. For example, it is hypothesised that reduced susceptibility to 
chlorhexidine, the most widely used antiseptic skin cleanser, may contribute to the endemic 
nature of Klebsiella pneumonia ST258 that is resistant to almost all available antibiotics and is 
associated with high morbidity and mortality.5 In other areas, for example the food and 
veterinary industries, alongside microorganisms such as P. aeruginosa and S. aureus, there are 
other persistent microorganisms such as Listeria monocytogenes and Escherichia coli which 
may cause food poisoning if they are not controlled or killed during food processing.   
Such interventions include developing new classes of biocides that have enhanced 
antimicrobial efficacy and which can be used to decontaminate surfaces in both food and 
hospital environments. Cationic antimicrobials have been widely deployed in antisepsis for 
well over half a century without any apparent reduction in their effectiveness.2 These molecules 
have been used in such items as medicated soaps, hand washes and bathing formulae. However, 
in recent years there has been movement towards the incorporation of these and other 
antimicrobial agents within polymer materials and coatings that comprise medical devices such 
as catheters and they have also been used in dressings and as topical antimicrobials.  
The importance in using novel antibacterial compounds in order to combat bacterial 
transmission and contamination has resulted in the development of various antibacterial 
polymer systems.6,7 In particular, conjugated polyelectrolytes (CPEs) have attracted much 
attention in recent years as a new class of materials.6,8-10 CPEs have been shown to demonstrate 
4 
 
antibacterial efficiency, which is mainly attributed to their charged structure.11,12 It has been 
shown that the addition of charged pendants to conjugated polymers has led to enhanced 
antibacterial activity, with both components seemingly necessary for potent acitvity.13,14 In 
some instances it has been shown that the conjugated backbone allows UV activation pathways 
resulting in alternative killing mechanisms which in combination with the charged pendants 
increases activity.12,14 Polyphenylene ethynylene (PPE) derivatives with positively charged 
quaternary ammonium (QA)  or alkylpyridinium or negatively charged sulfonate pendants have 
been found to be active against both Gram-negative and Gram-positive bacteria.8-10 It is 
hypothesized that such structural modifications enable these components to disrupt bacteria 
cell walls.15,16 The antibacterial efficiency of modified polyphenylene vinylene (PPV) has also 
been demonstrated against Bacillus subtilis and Escherichia coli where an increase in 
antimicrobial activity was again attributed to the addition of charged pendants.11 One strategy 
to further improve the antibacterial efficiency of CPEs is to amplify the overall charge which 
can be achieved by grafting of numerous charged sites onto a polymer backbone. Specifically, 
it may be advantageous to use amplified, positively-charged CPEs since charge increase has 
demonstrated a notably more efficient antimicrobial effect.17,18  
Among the various grafting polymerisation methods, atom transfer radical polymerisation 
(ATRP) has been extensively used for the synthesis of polymeric brushes.19,20 Moreover, these 
polymeric brushes have demonstrated antifouling efficiencies21-24 one example being, neutral 
2-(dimethylamino)ethyl methacrylate (DMAEMA) molecular brushes grafted onto glass or 
paper which showed significant antimicrobial efficacy against E. coli and B. subtilis.25 Other 
examples demonstrating antimicrobial activity using ATRP, include microsphere surfaces 
grafted quaternized PDMAEMA or poly(butylmethacrylate) grafted with poly(Boc-aminoethyl 
methacrylate). An alternative to standard ATRP is Activator ReGenerated by Electron Transfer 
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Atom Transfer Radical Polymerisation (ARGET ATRP) which has been shown to allow the 
synthesis of grafted copolymers with improved controllability.20,26 
We hypothesized that modification, via grafting, of the polymeric PPE and PPV macroinitiators 
may produce more efficient and effective biocidal materials. We therefore report on the 
preparation and properties of a range of antibacterial grafted conjugated-polymers. 
  
EXPERIMENTAL DETAILS 
Materials 
All reagents were purchased as a reagent grade from Sigma and used without further 
purification. Dichloromethane (DCM), tetrahydrofuran (THF), dimethylformamide (DMF) and 
methanol were all used as an analytical grade and dried before usage. 2-
(Methacryloyloxy)ethyl]trimethylammonium chloride (METAC) was used as a 30% solution 
in water. Solvents were dried using a solvent purifier (LC Technology Solutions Inc. SP-1 
Standalone Solvent Purifier System). 
 
Instruments 
A 300 or 400 MHz Bruker instrument was used for all NMR spectra recorded. IR spectroscopy 
was carried using a Perkin-Elmer Spectrum 1000 series Fourier Transform Infra-Red (FT-IR) 
ATR spectrometer, with a wavenumber range from 4000 to 400 cm−1. Mass spectrometry was 
carried out on a VG 70-SE Mass spectrometer using an electron-spray ionization method. UV-
Visible experiments were carried out on a Pharmaspec UV-1700, Shimadzu UV-Visible 
spectrophotometer using 3.5 mL quartz cuvettes. Solution-based fluorescence measurements 
were carried using a Perkin-Elmer LS 55 spectrophotometer with a 3-Q-10 mm rectangular 
quartz cell. The excitation wavelength was chosen as the maximum absorption wavelength of 
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the polymers. Molecular weight of the polymers were determined with a TDAmax GPC (Gel 
Permeation Chromatography) system (Malvern Instruments). GPC experiments were 
performed using the 2 x A5000 (300 mm x 8 mm each) Viscotech columns and A7Guard (50 
mm x 8mm) Guard column. A 0.02% NaN3 in water filtered through 0.02µm Nylon membrane 
filter (Grace) was used as an eluent with the flow rate of 1 mL/min. Before the injection all the 
samples were filtered through 0.22µm Nylon syringe filters (Grace). The columns and the 
detectors were maintained at 35 °C. Processing and acquisition of data was conducted using 
OmniSEC 4.7 software (Malvern Instruments) to achieve the calibration curve which was 
plotted using Dextran standards. The calibration curve was determined using dextran narrow 
standards purchased from Sigma-Aldrich. 
 
CPE synthesis 
The synthesis of dibromide 1 is given in the supporting information. The synthesis of PPVMI 
and PPEMI was performed as described previously, using Pd-catalyzed cross-coupling 
polymerization.27-29 To maximize the PPE and PPV yields the grafting of cationic brushes was 
performed post-polymerization. It was decided to incorporate a spacer group into the 
conjugated polymer backbones to enhance antibacterial efficiency by improving the grafting 
polymerization process. This would occur by minimizing the steric effect of neighbouring 
cationic grafted units during the grafting process. 
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Scheme 1: Synthesis of the grafted copolymers. 
To study the influence of the grafted cationic brushes, their density and the structure of the 
polymer backbones on the antibacterial efficiency, we grafted the cationic brushes onto 
dibromide 1, PPVMI and PPEMI (Scheme 1). The cationic brush graft density was varied by 
using either a 250:1 (Low) or 500:1 (High) mass ratio of METAC monomer when PPEMI and 
PPVMI were used.   
Initial attempts at grafting were made using traditional ATRP conditions, utilizing CuCl and 
N,N,N′,N′,N′′-pentamethyldiethylenetriamine (PMDETA) but resulted in grafted copolymers 
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with low molecular weight for all of the initiators used. Therefore, to improve the molecular 
weight of the grafted polymers, ARGET ATRP was then attempted.26 This method utilized 
CuCl2 and PMDETA as the catalyst and ligand, with excess ascorbic acid as the reducing agent, 
to generate reactive Cu(I) species in solution. As expected in the 1H NMR spectra signals 
corresponding to the initiators could not be observed after the grafting polymerization. This is 
consistent with previous reports as proton concentration of the polymer backbones becomes 
significantly lower than the grafted brushes.30,31 The formation of the grafted brushes were 
confirmed by the broadening of the METAC signals and the disappearance of the (CH2=CH) 
signals of the METAC monomer at 5.6-6.3 ppm, as well as the appearance of new peaks at 1.1-
2.0 ppm due to the formation of CH2-CH in the grafted polymer. 
 
 
 
Preparation of copolymer from dibromide 1  
The solution mixture of dibromide 1 (15 mg, 0.02 mmol) in DMSO (5 mL) was added to a 
solution of 2-(methacryloyloxy)ethyl]trimethylammonium chloride (METAC) (1.88 mL, 10 
mmol) in DMSO (10 mL) and water (0.6 mL) and left at r.t. to achieve a clear solution. The 
ligand-catalyst complex was prepared by adding N,N,N′,N′′,N′′-pentamethyldiethylenetriamine 
(PMDETA) (7.5 mg, 0.041 mmol) to CuCl2 (2 mg, 0.0148 mmol) in anisole (1 mL) at 67 °C. 
The ligand-catalyst complex was added to the reaction mixture and heated to 60 °C. A mixture 
of ascorbic acid (980 mg, 5.56 mmol) in anisole (1 mL) and water (0.30 mL) was added slowly 
to the reaction and left for 24 h under an atmosphere of nitrogen at 60 °C. After this time the 
reaction was quenched with exposure to air and cooling the reaction flask in liquid nitrogen. 
The precipitated grafted polymer was then filtered and dissolved in water (5 mL). The grafted 
polymer was then re-precipitated into acetone (100 mL) and centrifuged to collect the product 
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as a white solid (78 mg, 42 %). δH (300 MHz; D2O): 4.35-4.52 (2H, m, CH2); 3.70-3.77 (2H, 
m, CH2); 3.22 (9H, s, CH3); 1.95-2.02 (1H, m, CH); 1.31-1.55 (2H, m, CH2). GPC: Mw: 
6.41×103, Mn: 4.98×10
3, Mw/Mn: 1.29 
Preparation of copolymers from PPVMI 
A solution of PPVMI (270 mg, 0.01 mmol) in DMSO (5 mL) was added to a solution of 
METAC (1.88 mL, 10 mmol) in DMSO (5 mL) and water (600 µL) whilst stirring, to give a 
colourless solution. Separately the ligand-catalyst complex was prepared by adding PMDETA 
(7.5 mg, 0.041 mmol) into a mixture of CuCl2 (2 mg, 0.0148 mmol) mixture in anisole (1 mL) 
at 67 °C for 3 h. This complex was added to the reaction mixture at 60 °C. Then a solution of 
ascorbic acid (980 mg, 5.56 mmol) in anisole (1 mL) and water (300 µL) was added slowly to 
the reaction and left for 24 h under an atmosphere of nitrogen at 60 °C. The reaction was 
quenched by cooling the mixture with liquid nitrogen and exposing the mixture to air. The 
orange precipitate was collected and then dissolved in water. The product was re-precipitated 
using acetone (100 mL) and collected using centrifuge to give a bright orange solid (850 mg, 
55 %). δH (400 MHz; D2O): 1.01-1.10 (2H, m, CH2), 1.95-2.01 (1H, m, CH), 3.25 (9H, br s, 
CH3), 3.75-3.82 (2H, m, CH2), 4.45-4.50 (2H, m, CH2). GPC: Mw: 77.50×10
3, Mn: 46.19×10
3, 
Mw/Mn: 1.68. λmax abs = 435 nm. λmax em =  535 nm. The same procedure was used to achieve the 
low molecular weight PPV-g- METAC, except using METAC (950 µL, 5 mmol) in DMSO (5 
mL) and water (300 µL) and ascorbic acid (600 mg, 3.40 mmol) in anisole (1 mL) and water 
(150 µL) to give a bright orange solid (180 mg, 40 %). δH (400 MHz; D2O): 1.01-1.10 (2H, m, 
CH2), 1.92-2.03 (1H, m, CH), 3.28 (9H, br s, CH3), 3.77-3.85 (2H, m, CH2), 4.43-4.48 (2H, m, 
CH2). GPC :  Mw: 22.87×10
3, Mn: 16.72×10
3, Mw/Mn: 1.37. λmax abs = 435 nm. λmax em = 537 
nm. 
Preparation of copolymer from PPEMI  
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A solution of PPEMI (220 mg, 0.02 mmol) in DMSO (5 mL) was added to a solution of 
METAC (1.88 mL, 10 mmol) in DMSO (5 mL) and water (600 µL) whilst stirring, to give a 
colourless solution. Separately, the ligand-catalyst complex was prepared by adding PMDETA 
(7.5 mg, 0.041 mmol) into a mixture of CuCl2 (2 mg, 0.0148 mmol) in anisole (1 mL) at 67 °C 
for 3 h. This complex was added to the reaction mixture at 60 °C. Then a solution of ascorbic 
acid (980 mg, 5.56 mmol) in anisole (1 mL) and water (300 µL) was added slowly to the 
reaction and left for 24 h under an atmosphere of nitrogen at 60 °C. The reaction was quenched 
by cooling the mixture with liquid nitrogen and exposing the mixture to air. The orange 
precipitate was collected and then dissolved in water. The product was re-precipitated using 
acetone (100 mL) and collected using centrifuge to achieve a bright orange solid (870 mg, 
63 %). δH (400 MHz; D2O): 1.02-1.11 (2H, m, CH2), 1.97-2.03 (1H, m, CH), 3.26 (9H, br s, 
CH3), 3.77-3.82 (2H, m, CH2), 4.47-4.51 (2H, m, CH2). GPC: Mw: 77.48×10
3, Mn: 46.03×10
3, 
Mw/Mn: 1.68. λmax abs = 428 nm. λmax em = 493 nm. The same procedure was used to achieve the 
low molecular weight PPE-g-METAC, except using METAC (950 µL, 5 mmol) in DMSO (5 
mL) and water (300 µL) and a solution of ascorbic acid (600 mg, 3.40 mmol) in anisole (1 mL) 
and water (150 µL) to give a bright orange solid (190 mg, 43 %).  δH (400 MHz; D2O): 1.04-
1.13 (2H, m, CH2), 1.95-2.01 (1H, m, CH), 3.24 (9H, br s, CH3), 3.78-3.83 (2H, m, CH2), 4.45-
4.47 (2H, m, CH2). GPC: Mw: 21.97×10
3, Mn: 16.20×10
3, Mw/Mn: 1.36. λmax abs = 428 nm. λmax 
em = 497 nm. 
 
ARGET ATRP Kinetic Studies 
As the grafting polymerisation was indicated to be successful within the ARGET ATRP the 
controllability of this reaction was studied whilst monitoring the polymerisation using 1H 
NMR. Therefore at specific intervals, 100 μL samples were taken from the reaction. The 
monomer conversion was monitored using anisole as an internal standard.  
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Bacterial Preparation 
All bacteria (Methicillin resistant Staphylococcus aureus (MRSA) NCTC 13552, Escherichia 
coli NCTC 10418, Acinetobacter baumannii NCTC 12156, Klebsiella pneumoniae NCTC 
9633 and Pseudomonas aeruginosa NCTC 10332) were grown on tryptone soya agar (TSA) 
and in tryptone soya broth (TSB) at 37°C except E. faecium which was grown in brain heart 
infusion (BHI) broth on Columbia blood agar with added defibrinated horse blood in a CO2 
environment at 37°C. All microbiological agars and broths were purchased from Oxoid, (UK). 
A single colony of the bacteria was inoculated from agar into 100 mL of microbiological media. 
The inoculated culture was incubated at 3000 rpm in an air environment for 24 h, with the 
exception of E. faecium which was grown in a 5 % CO2 incubator without shaking for 24 h. 
Cells were harvested by centrifugation (3500 × g for 10 min) and then washed with 10 mL 
sterile distilled water and vortexed to ensure even distribution of the cell suspension. The 
washed cells were again re-harvested. The pellet was re-suspended in 10 mL of broth, vortexed 
and the resultant cell suspension was adjusted to an optical density at 540 nm (OD540) of 1.0 
using a spectrophotometer (Jenway 6305 UV/Visible Spectrophotometer). The cell 
concentrations corresponded to 1.0 – 4.0 x 108 colony-forming units per mL (CFU mL-1) at an 
OD540 of 1.0.  
 
Zone of Inhibition (ZoI) assays 
The appropriate agar (25 mL) was poured into sterile Petri dishes, which were then cooled and 
100 µL of cell suspension was pipetted and spread across the entire area of the agar. Three 
equal wells (8 mm diameter) were cut out of the each agar plate using a sterile cork borer and 
a stainless steel needle. The borer and needle were sterilised in 70 % ethanol and flamed before 
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use. To each individual well, 100 µL CPE (5mg/L) was added. The plates were incubated under 
the appropriate conditions for 24 h. Following incubation, the ZoI was measured in mm from 
four sides of each well to determine an average mean value.  
 
MIC and MBC assays 
Bacteria were grown and prepared to an OD 1.0 as above. One millilitre of Triphenyl 
tetrazolium chloride (TTC) blue metabolic dye (Sigma-Aldrich, UK), was added into 9 mL of 
the cell suspension so that the working concentration of the dye was 0.15 % w/v. To determine 
the MIC, 100 µL of the test samples and acid controls were added to a 96 well flat-bottomed 
micro titre plate (MTP). One hundred microliters of bacterial suspension with the TTC dye was 
then added using a multi-channel pipette; the first column of cell/metal ion suspension was 
mixed, then 100 µL of the sample/bacterial mix was transferred to the column 2 wells. The 
dilution method was repeated until column 10 upon which 100 µL of the mixture was disposed 
of. To column 11, 100 µL of bacterial suspension without any CPE (positive control) was added 
and to column 12 and 100 µL of un-inoculated broth was added (negative control). After 
incubation, the MIC was taken as lowest concentration that inhibited the visible growth of the 
bacteria by comparison with the controls. Growth was indicated by a change of colour in the 
well to dark blue/purple. Twenty-five microliters of culture was taken from the first well that 
showed no growth and the last well that demonstrated growth and was pipetted onto agar plates 
using Miles and Misra methodology. After incubation, the lowest concentration well sample 
that showed no bacterial growth on the agar plate was determined to be the MBC for that test 
sample. 
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RESULTS AND DISCUSSION 
 
PPV and PPE were chosen as the backbones for this investigation as a comparison of these two 
related backbones can provide an insight into how subtle changes affect the grafting of the 
brushes, and how their graft density/length can affect subsequent antibacterial efficiency.  
Polymerization kinetics were studied using 1H NMR spectroscopy to determine the 
controllability of polymerization and to evaluate the monomer conversion rate with both 
PPVMI and PPEMI using low and high monomer ratios. This was done by tracking the 
decrease in the integration of the (CH2=CH) signals relative to integration of anisole (internal 
standard) (Figure 1).  All of the kinetic studies demonstrate biphasic behaviour; with fast initial 
rates up to 35 min, followed by a slower rate. Such a fast initial rate is related to the higher 
monomer to initiator concentration ratio at the beginning of the grafting polymerization.32 The 
slower kinetics beyond 30 min of the reaction time exhibits an almost linear behaviour which 
suggests a degree of controllability. 
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Figure 1. Kinetic model study of PPE-g-PMETAC and PPV-g-PMETAC with high and low 
molecular weight grafting polymerisation. 
The anti-microbial activity of the synthesised cationic grafted polymers was assessed, using 
zone of inhibition (ZoI) measurements, against a range of pathogens including Enterococcus 
faecium, Methicillin resistant Staphylococcus aureus (MRSA), Escherichia coli, Acinetobacter 
baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa. It was determined that both 
the high and low molecular weight cationic compounds were particularly effective against all 
the Gram positive bacteria (E. faecium and MRSA) and also against Gram negative E. coli 
(Figure 2). Non-grafted backbones, PPVOH and PPEOH and 1-g-PMETAC did not 
demonstrate any antimicrobial activity. Thus, it may be speculated that the nature of side chain 
attachment to the polymer backbone influenced the antimicrobial efficacy of the compound 
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when tested using a semi-solid media method. The density of cationic grafts (high or low) did 
not affect the antimicrobial activity under these assay conditions. 
 
Figure 2. Antimicrobial activity of the compounds against a range of Gram negative and Gram 
positive bacteria using semi-solid agar tests. All compounds tested shown no activity against 
A. baumanni, K. pneumoniae and P. aeruginosa in this assay.   
Next, minimal inhibitory concentration (MIC) and minimal bactericidal concentration assays 
(MBC) were carried out. The MIC of the compounds were determined to demonstrate the 
inhibition of the compounds on bacterial growth, whereas the MBC determine the bactericidal 
activity of the compounds.  These antimicrobial assays were carried out in a microbiological 
media solution. Unlike the ZOI testing, MIC results demonstrated that PPVOH and PPEOH 
demonstrated good antimicrobial efficacy against all the bacteria tested (0.63 mg/L to 5.00 
mg/L). Against E. faecium PPE-g-PMETAC (HMw), PPE-g-PMETAC (LMw), PPV-g-
PMETAC (HMw) and PPV-g-PMETAC (LMw), that is all compounds combining conjugated 
backbone with cationic side chains, demonstrated excellent antimicrobial activity (0.02 mg/L). 
This was also demonstrated in the MBCs (0.16 mg/L – 0.31 mg/L). All the compounds 
inhibited and were bactericidal against MRSA and E. coli with PPE-g-PMETAC (LMw) 
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demonstrating the best antimicrobial activity (0.01 mg/L MIC and 0.02 mg/L MBC against 
MRSA and 0.02 mg/L MIC and 0.04 MBC against E. coli). Against K. pneumonia and P. 
aeruginosa similar trends were demonstrated whereby the PPVOH and the PPEOH 
demonstrated the greatest antimicrobial activities (MIC: 1.25 mg/L and 0.63 mg/L, MBC: 2.5 
mg/L and 2.5mg/L for K. pneumonia and A, baumannii, respectively). A. baumannii was also 
most affected by PPVOH and PPEOH (MIC 0.31 mg/L, MBC 1.25 mg/L for both compounds), 
but the most antimicrobial compound against this bacteria was again PPE-g-PMETAC (LMw) 
(MIC 0.16 mg/L, MBC 0.63 mg/L). 
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Figure 3. a) Minimal inhibitory concentration (MIC) and b) minimal bactericidal 
concentrations (MBC) of synthesised compounds against the bacteria investigated. 
The positive results of these cationic compounds is comparable to other studies, where cationic 
compounds have been highly effective antimicrobials.33 PPE derivatives containing short 
trimethylammonium pendants (total number of cationic sites ~14) have been shown to be active 
at concentrations of 1 mg/L against E. coli,34 whilst PPE-g-PMETAC (LMw) had an improved 
MBC of 0.039 mg/L against the same bacteria. 
The outermost surface of bacterial cells carries a net negative charge. This is associated with 
the teichoic acid and polysaccharide elements of Gram positive bacteria, the lipopolysaccharide 
of Gram-negative bacteria, and the cytoplasmic membrane itself, thus cationic agents have a 
high binding affinity for bacterial cells.2 The results demonstrated that the PPE-g-PMETAC 
(LMw) was the most effective antimicrobial overall. In the ZOI assays, all the conjugated 
polymers bearing cationic side chains demonstrated antimicrobial activity against E. faecium, 
MRSA and E. coli. These results reflect the ability of these polymers to be dispersed in a 
semisolid media, most likely to their high aqueous solubility, resulting from extensive cationic 
groups. However, in the MIC and MBC assays, the compounds demonstrated a range of 
efficacies that were dependent on both the chemical structure of the compound and the cell 
type. Against E. faecium all the compounds with the cationic grafts were antimicrobial, 
whereas against MRSA and E. coli the most antimicrobial polymer was the PPE-g-PMETAC 
(LMw). In contrast against K. pneumoniae and A, baumannii the ungrafted PPVOH and 
PPEOH were the most antimicrobially effective. 
Among vegetative bacteria, Gram-negative are deemed to be the least sensitive to biocides, 
followed by Gram-positive bacteria, however this classification is primarily based on the 
difference in permeability/impermeability of the micro-organism to an active agent.35 This is 
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especially important in the resistant ESKAPE bacteria where differences in their cell wall 
structure and components leads to varying responses to biocides.36 Certain cationic biocides 
(e.g. chlorhexidine) are considered to penetrate the cell by a mechanism of self-promoted 
uptake, which may lead to induce the formation of permeable pores in the bacterial envelope.37 
However, our work demonstrated that E. coli was particularly susceptible to the majority of the 
compounds tested, as was MRSA. E. faecium may have been more resistant than the MRSA to 
the compounds since it is difficult to inactivate due to high level recalcitrance and it can tolerate 
a wide range of growth conditions and can also survive for long periods of time on 
environmental surfaces.38,39 This difference in the effect of the compounds may also be 
explained because the Gram negative bacteria used in this work have different physiologies. In 
E. coli the cell wall is thought to be only around 4 nm in thickness.40 However, K. pneumoniae 
has a large polysaccharide capsule surrounding the bacterial cell, which both protects the 
bacteria and acts as a barrier to antimicrobial agents.41 A. baumannii is an encapsulated Gram-
negative coccobacilli bacteria whose features on the outer cell membrane include porins and 
efflux channels which contribute to antibiotic resistance. A. baumannii has fewer and smaller 
porins than other Gram-negative bacteria, thereby decreasing cell permeability and increasing 
antibiotic resistance.42 It has been suggested that less than 5% of molecules are permeable to 
the cell membrane, which is less than that found in Escherichia coli.42 This may be in part why 
A. baumannii was less affected by the biocides in our study than was E. coli. P. aeruginosa is 
intrinsically resistant to antimicrobial agents due to low permeability of its cell wall.43 A 
characteristic feature of many P. aeruginosa strains is the production of a loosely associated 
layer of the anionic polysaccharide, alginate, which surrounds the cells and binds them together 
in aggregates and it has been shown that alginate can bind cationic antibiotics such as the 
aminoglycosides and restrict their diffusion.44 The different results with these compounds 
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suggest their killing mechanism is more complex than just membrane disruption and this will 
be investigated in future work. 
 
Conclusions  
Whilst PPE and PPV derivatives have been previously found to be active against both Gram-
negative and Gram-positive bacteria, previous molecules contained fewer charged sites.8-
10,11,13,14 By using ARGET ATRP, the antibacterial efficiency of these CPEs was amplified by 
grafting additional cationic sites onto the conjugated backbones. The benefit of this approach 
is that the same conjugated macroinitiator (such as PPVMI or PPEMI) can be used to add 
various cationic grafted brushes without the need for redesigning of the CPE backbone.  
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